Success Stories: With Our Meticulous Efforts, An Indian Associate Director Secured his EB1-A Approval in the Field of Biostatistics in just 10 days, Premium Processing Requested

 

Client’s Testimonial:

“Thank you for the great news! I really appreciate your good work.”

---

On March 3^rd, 2023, we received another EB-1A (Alien of Extraordinary Ability) approval for an Associate Director in the Field of Biostatistics (Approval Notice).

---

General Field: Biostatistics

Position at the Time of Case Filing: Associate Director

Country of Origin: India

State of Residence at the Time of Filing: New Jersey

Approval Notice Date: March 3^rd, 2023

Processing Time: 10 days (Premium Processing Requested)

---

Case Summary:

An Associate Director approached North America Immigration Law Group to file his alien of extraordinary ability (EB1-A) petition. Hailing from India, he has completed his Ph.D. in biostatistics and is also currently employed in the same field.

Since a petition for the first preference category of individuals with extraordinary ability (“EB1-A”) unlike the employment-based immigration visa under the second preference (“EB-2”), at least requires the following:

• Evidence of original contributions, usually through publication, of major significance in the foreign national’s field of science, scholastic, artistic, or athletic.
• No specific job offer/labor certification is required for a foreign person as long as he/she is entering the United States to continue work in the field in which he/she has an extraordinary ability, therefore self-petition is allowed.
• Performance in a significant role for organizations or establishments that have a distinguished reputation.
• Receipt of a higher salary or remuneration than is usual in the field.
• Other comparable evidence if the above types of evidence do not readily apply to the foreign national’s occupation.

Therefore, we included the following essentials from his academic and professional records in his petition packet to make a convincing case in his favor:

• His data-driven diagnostics/prognostics, clinical trial evaluation, and risk estimation research address some of our nation’s and the world’s most pressing issues, including understanding the benefits and drawbacks of patient isolation and contact precautions, early decision-making for cancer treatments, and new tools to identify subsets in groups of patients to target with personalized medicine.
• His research has resulted in 26 peer-reviewed scientific articles, being cited 493 times in at least 43 countries.
• He has conducted at least 40 reviews for at least 10 journals.

Our client’s work has thus been majorly significant, and his achievements are of the utmost importance due to their direct applicability in global efforts to address work on data-driven clinical practices and public health.

Five fellow experts in the field further provided insight into the significance of his continuing research, one of whom remarked:

“[Client’s] work in this regard, and indeed, his overarching research agenda, affects widely held interests in global public health. His work is focused on accurate, efficient, and powerful statistical analysis of clinical data (i.e., diagnostic and clinical trial data), which also provides significant benefits for the field in terms of clinical decision-making, drug development, and clinical trials. Overall, [client] is instrumental in transitioning the medical field from traditional practices to data-driven, evidence-based medicine, which affects not only patient attitudes but also the development and delivery of novel therapeutics to patients around the world.”

Finally, he achieved his EB1-A (Alien of Extraordinary Ability) approval in just 10 days (thanks to premium processing) with our firm’s consistent support and dedication. He has even filed an I-485 case with us. We are happy to have been a part of his successful journey and wish him a flourishing life ahead.

---